The protocol at a glance
There is no human dose. In mice, KPV was given in drinking water and reduced gut inflammation.
| Item | What is known |
|---|---|
| Human dose | Not established |
| Studied in | Mice (in drinking water) and human cells in dishes |
| Human trials | None found |
Dalmasso 2008 (Gastroenterology). The abstract does not give the mouse dose. A search of ClinicalTrials.gov for KPV returned no studies.
Community reports commonly describe 200 to 500 mcg by mouth, once or twice a day. These are user reports, not trial doses.
What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.
Mixing
No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.
What the trials found
No human results exist. In mice (two colitis models), by mouth in drinking water:
Dalmasso G et al. Gastroenterology 2008 (DSS and TNBS colitis in mice); Viennois E et al. Cell Mol Gastroenterol Hepatol 2016.
Side effects
- There is no human safety data for KPV.
How it works
Gut transporter PepT1 (lab data)
In cell and mouse work, KPV enters gut and immune cells through a transporter called PepT1. Inside, it dampens the NF-kB and MAP kinase inflammation signals.
Sources
- Dalmasso G et al. Gastroenterology 2008, PMID 18061177
- Viennois E et al. Cell Mol Gastroenterol Hepatol 2016, PMID 27458604
- ClinicalTrials.gov search for KPV: no studies
- Drugs@FDA / openFDA search: no KPV product